Terminal Complement Inhibition for Refractory IgA‐Mediated Autoimmune Hemolytic Anemia in a Pediatric Heart Transplant Recipient
Pediatric Blood & Cancer · 2026-10 · 73 (10)
DOI: 10.1002/1545-5017.70555 ↗Kurz gefasst
Leserbrief in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 25.07.2026. Verfasst von Akhila Arcot Vadivelan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cancer and Blood Disorders, Children's Hospital of Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
: We describe a case of Coombs-negative autoimmune hemolytic anemia (AIHA) mediated by IgA autoantibodies in a post–heart transplant patient, diagnosed using extended direct antiglobulin test (DAT) and successfully managed with complement inhibition using eculizumab. AIHA is a rare disorder characterized by immune-mediated destruction of red blood cells, most commonly due to IgG autoantibodies in warm AIHA [ 1, 2 ]. The diagnosis is established using the DAT, which detects immunoglobulin and/or complement components bound to erythrocytes [ 1 ]. However, approximately 5%–10% of patients with clinical features consistent with AIHA have a negative DAT using standard methods, leading to the entity of Coombs-negative AIHA [ 3 ]. Mechanisms proposed for DAT negativity include low-affinity antibodies, low antigen density, or the presence of immunoglobulin classes not detected by routine reagents, particularly IgA [ 3, 4 ]. IgA-mediated AIHA represents a rare, severe subtype, with only sporadic cases described in the literature [ 5 ]. Because standard DAT reagents primarily detect IgG and complement (C3), IgA autoantibodies may be missed unless monospecific anti-IgA reagents are used, often referred to as extended or “super Coombs” testing [ 6 ]. Clinically, IgA-mediated AIHA can present
Autor:innen und Institutionen
- Center for Cancer and Blood Disorders, Children's Hospital of Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.
- Heart Institute, Children's Hospital of Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.
ORCID-Profile: Akhila Arcot Vadivelan, Melanie D Everitt
Zitieren
APA
Vadivelan, A. A., Nakano, T., & Everitt, M. D. (2026). Terminal Complement Inhibition for Refractory IgA‐Mediated Autoimmune Hemolytic Anemia in a Pediatric Heart Transplant Recipient. Pediatric Blood & Cancer, 73(10). https://doi.org/10.1002/1545-5017.70555
Vancouver
Vadivelan AA, Nakano T, Everitt MD. Terminal Complement Inhibition for Refractory IgA‐Mediated Autoimmune Hemolytic Anemia in a Pediatric Heart Transplant Recipient. Pediatric Blood & Cancer. 2026;73(10). doi:10.1002/1545-5017.70555
BibTeX
@article{Vadivelan2026,
author = {Vadivelan, Akhila Arcot and Nakano, Taizo and Everitt, Melanie D},
title = {Terminal Complement Inhibition for Refractory IgA‐Mediated Autoimmune Hemolytic Anemia in a Pediatric Heart Transplant Recipient},
journal = {Pediatric Blood & Cancer},
year = {2026},
volume = {73},
number = {10},
doi = {10.1002/1545-5017.70555}
}
EUVIMED